{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-096269","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.055520+00:00","generated_at":"2026-05-30T02:14:13.331111+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Citius Oncology reports 27% ORR, 33% CBR in Phase I trial of LYMPHIR + pembrolizumab for recurrent solid tumors","bullets":["27% objective response rate (4/15 evaluable) and 33% clinical benefit rate (5/15) in heavily pre-treated gynecologic tumors.","Median progression-free survival of 57 weeks (range 30-96 weeks) for patients achieving clinical benefit.","Combination was well-tolerated with no documented ≥Grade 3 immune-related adverse events; one dose-limiting toxicity (capillary leak) at 12 mcg/kg.","Two of four partial responders had failed prior anti-PD-1 therapy, suggesting potential to overcome checkpoint resistance.","Trial nearing completion with three additional patients to enroll; data presented at SITC 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-096269","json":"https://secwatch.observer/filing/0001213900-24-096269.json","markdown":"https://secwatch.observer/filing/0001213900-24-096269.md","text":"https://secwatch.observer/filing/0001213900-24-096269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/0001213900-24-096269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/ea0220666-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:14:13.331111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}